CNS Pharmaceuticals, Inc.
CNSP
$5.78
-$0.16-2.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.50M | 1.43M | 2.82M | 1.06M | 1.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.70M | 4.98M | 5.99M | 3.25M | 2.41M |
| Operating Income | -2.70M | -4.98M | -5.99M | -3.25M | -2.41M |
| Income Before Tax | -2.59M | -4.94M | -5.96M | -3.22M | -2.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.59M | -4.94M | -5.96M | -3.22M | -2.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.59M | -4.94M | -5.96M | -3.22M | -2.38M |
| EBIT | -2.70M | -4.98M | -5.99M | -3.25M | -2.41M |
| EBITDA | -2.69M | -4.97M | -5.99M | -3.25M | -2.41M |
| EPS Basic | -0.38 | -7.30 | -9.70 | -5.76 | -6.42 |
| Normalized Basic EPS | -0.24 | -4.56 | -6.06 | -3.60 | -4.01 |
| EPS Diluted | -0.38 | -7.30 | -9.70 | -5.76 | -6.42 |
| Normalized Diluted EPS | -0.24 | -4.56 | -6.06 | -3.60 | -4.01 |
| Average Basic Shares Outstanding | 6.84M | 676.20K | 613.80K | 558.90K | 370.10K |
| Average Diluted Shares Outstanding | 6.84M | 676.20K | 613.80K | 558.90K | 370.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |